Together We Are Stronger!
OACS Ireland is a voluntary support group.
We aim to provide support and information to other families,
whose children have been effected by Fetal Anti-Convulsant Syndrome (F.A.C.S) in Ireland.
National Conference on the Consequences of Sodium Valproate (Epilim): 50 years on
For patients & families, healthcare professionals and policy makers
Organised by the Health Service Executive, Epilepsy Ireland, OACS Ireland, Trinity College Dublin and the FACS Forum
Friday March 22nd 2019
9.30am – 5pm
Stanley Quek Theatre
Biomedical Sciences Institute | Trinity College Dublin
152-160 Pearse Street | Dublin 2
Sodium Valproate (Epilim) is a medication used to treat epilepsy and bipolar disorder. The European Medicines Agency has restricted its use in women due to the increased risk of disabilities in children exposed to Valproate in the womb (Foetal Valproate Syndrome).
This conference will address the key issues today facing families, healthcare professionals and policy makers in:
The pharmacology of sodium valproate
Sodium valproate: Who knew what and when?
Reducing the risks associated with sodium valproate
Diagnosing and managing foetal valproate syndrome
Living with foetal valproate syndrome and the consequences of sodium valproate
The Irish Health Service’s response to the valproate problem
Dr Colm Henry, HSE Chief Clinical Officer
Karen Keely, Chairperson, OACS Ireland
Dr Jeff Aronson, Clinical Pharmacologist, Centre for Evidence-Based Medicine, Oxford
Prof. Carl Heneghan, Director of the Centre for Evidence-Based Medicine, Oxford
Prof. Amanda Wood, Professor of Developmental Neuropsychology, Aston University, Birmingham
Dr Peter Turnpenny, Clinical Geneticist, Royal Devon & Exeter Hospital, UK
Prof. Andrew Green, Consultant Clinical Geneticist, Our Lady's Children's Hospital, Crumlin
Families affected by Foetal Valproate Syndrome
Members of the HSE’s Valproate Response project team
For further information, please contact:
Sabrina Doyle, HSE: 01 6352508 | firstname.lastname@example.org